দেশ: ইন্দোনেশিয়া
ভাষা: ইন্দোনেশীয়
সূত্র: Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency
TAZOBACTAM SODIUM, CEFTOLOZANE SULFATE
ORGANON PHARMA INDONESIA TBK - Indonesia
TAZOBACTAM SODIUM, CEFTOLOZANE SULFATE
537 MG /1147 MG
SERBUK INFUS
DUS, 10 VIAL @ 1.5 G
Steri-Pharma LLC - United States of America
2021-08-05
ZERBAXA™ (CEFTOLOZANE AND TAZOBACTAM) POWDER FOR INFUSION ZERBAXA (ceftolozane and tazobactam) for injection is indicated for the treatment of patients 18 years or older with the following infections caused by designated susceptible microorganisms: COMPLICATED INTRA-ABDOMINAL INFECTIONS ZERBAXA used in combination with metronidazole is indicated for the treatment of patients with complicated intra-abdominal infections (cIAI) and required surgical intervention (e.g., laparotomy, laparoscopic surgery, or percutaneous draining of an abscess) within 24 hours of (before or after) the first dose of Zerbaxa. These cIAI are caused by the following Gram-negative and Gram-positive microorganisms: Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatu s, and Streptococcus salivarius . COMPLICATED URINARY TRACT INFECTIONS, INCLUDING PYELONEPHRITIS ZERBAXA is indicated for the treatment of patients with complicated urinary tract infections (cUTI) and pyuria with at least one of the following new or worsening symptoms (dysuria, frequency, suprapubic pain, urgency) and at least one of the following complicating factors (current bladder instrumentation, obstructive uropathy, urogenital surgery, functional or anatomical abnormality of the urogenital tract), including pyelonephritis, with or without concurrent bacteremia, caused by the following Gram-negative microorganisms: Escherichia coli , Klebsiella pneumoniae , Proteus mirabilis , and Pseudomonas aeruginosa . HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA OR VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP / VABP) ZERBAXA is indicated for the treatment of patients 18 years and older with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia caused by the following susceptible Gram-negative microorganisms: Enterobacter cloacae, Escherichia coli, Haemophilus influenza, Klebsiella oxytoca, Klebsiella pneumoniae, Pro সম্পূর্ণ নথি পড়ুন